FCGR3A and cancer: Subsequently, the ADCC of BiKE:HER2/CD16a against HER2+ cancer cells was measured using both haNK92 (CD16+, V176) and laNK92 (CD16+, F176) cells as effector cells and compared with TrazimeraTM (trastuzumab).